96 related articles for article (PubMed ID: 4130904)
21. [A "myeloproliferative syndrome" of long duration (author's transl)].
Kühböck J; Peskar BM; Vormittag W
Med Klin; 1974 Mar; 69(10):423-6. PubMed ID: 4524608
[No Abstract] [Full Text] [Related]
22. [Pulmonary hypertension in chronic myeloproliferative disorders].
Einsfelder BM; Müller KM
Pathologe; 2005 May; 26(3):169-77. PubMed ID: 15257414
[TBL] [Abstract][Full Text] [Related]
23. Hematopathologic findings in the myeloproliferative disorders.
Dickstein JI; Vardiman JW
Semin Oncol; 1995 Aug; 22(4):355-73. PubMed ID: 7638633
[TBL] [Abstract][Full Text] [Related]
24. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
25. [Splenoma with accumulation of megakaryocytes during the course of an idiopathic myelofibrosis].
Brouland J; Molina T; Delmer A; Zittoun R; Diebold J
Ann Pathol; 1994; 14(1):32-5. PubMed ID: 8155190
[TBL] [Abstract][Full Text] [Related]
26. [Myelofibrosis (author's transl)].
Hunstein W; Hauswaldt C
Klin Wochenschr; 1974 Apr; 52(7):305-17. PubMed ID: 4601278
[No Abstract] [Full Text] [Related]
27. Pleural extramedullary haematopoiesis in myelosclerosis.
Anton HC; Ferguson JB; Lewis GP
Postgrad Med J; 1967 Jun; 43(500):428-32. PubMed ID: 6043695
[No Abstract] [Full Text] [Related]
28. [Megakaryopoiesis in chronic myeloproliferative disorders].
Nagasawa T
Rinsho Ketsueki; 1993 May; 34(5):551-6. PubMed ID: 8315826
[TBL] [Abstract][Full Text] [Related]
29. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
Garber K
J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
[No Abstract] [Full Text] [Related]
30. Diagnostic parameters of altered collagen turnover.
Hahn EG; Hochweiss S; Berk PD
Prog Clin Biol Res; 1984; 154():335-43. PubMed ID: 6382302
[No Abstract] [Full Text] [Related]
31. Idiopathic myelofibrosis. Clinical aspects and studies on extracellular matrix metabolism.
Hasselbalch HC
Dan Med Bull; 1993 Mar; 40(1):39-55. PubMed ID: 8472598
[No Abstract] [Full Text] [Related]
32. [Pathogenesis of marrow fibrosis in myeloproliferative disorders].
Wróbel T; Podolak-Dawidziak M
Pol Arch Med Wewn; 1998 Jan; 99(1):70-7. PubMed ID: 9686507
[No Abstract] [Full Text] [Related]
33. [TGF-beta and platelet].
Kogawa K; Mogi Y; Morii K; Takimoto R; Niitsu Y
Rinsho Ketsueki; 1994 Apr; 35(4):370-5. PubMed ID: 8028182
[TBL] [Abstract][Full Text] [Related]
34. [Vascular changes in bone marrow in blood diseases].
Demmler K; Burkhardt R
Med Klin; 1980 Apr; 75(9):328-32. PubMed ID: 7402170
[No Abstract] [Full Text] [Related]
35. [Benign subleukemic myelosis].
Abramov MG
Ter Arkh; 1974; 46(8):13-9. PubMed ID: 4421213
[No Abstract] [Full Text] [Related]
36. New molecular insights in myelodysplastic and myeloproliferative disorders.
Emanuel PD
Clin Adv Hematol Oncol; 2005 Jun; 3(6):459-60. PubMed ID: 16167021
[No Abstract] [Full Text] [Related]
37. [Characteristic features of infections in hemoblastoses under cytostatic treatment (author's transl)].
Paulisch R; Koeppen KM
MMW Munch Med Wochenschr; 1976 May; 118(21):661-4. PubMed ID: 818543
[TBL] [Abstract][Full Text] [Related]
38. Thrombohemorrhagic complications of myeloproliferative disorders.
Papadakis E; Hoffman R; Brenner B
Blood Rev; 2010 Nov; 24(6):227-32. PubMed ID: 20817333
[TBL] [Abstract][Full Text] [Related]
39. Myelofibrosis revisited: characterization and classification of myelofibrosis in the setting of myeloproliferative disease.
Gilbert HS
Prog Clin Biol Res; 1984; 154():3-17. PubMed ID: 6382299
[TBL] [Abstract][Full Text] [Related]
40. Morphological studies on the bone tissue of sternum in osteomyelosclerosis, panmyelosis and chronic myeloleukosis.
Velizarov A; Valkov I
Nauchni Tr Vissh Med Inst Sofiia; 1970; 49(3):61-71. PubMed ID: 4253273
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
